Yuji Kurihara
5PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jun 30, 2020
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).Kazunori Utsunomiya, Ryusuke Koshida, Seigo Kakiuchi
|Feb 09, 2020
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda
|Aug 08, 2019
Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study).Kohei Kaku, Yusuke Naito, Masayuki Senda
|Jun 15, 2019
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi
|Apr 30, 2019
Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara
Pageof 1
